Last reviewed · How we verify

Lactobacillus plantarum strain 299

Children's Oncology Group · Phase 3 active Biologic

Lactobacillus plantarum strain 299 is a probiotic bacterium that modulates the gut microbiome and intestinal barrier function to support immune homeostasis.

Lactobacillus plantarum strain 299 is a probiotic bacterium that modulates the gut microbiome and intestinal barrier function to support immune homeostasis. Used for Prevention or mitigation of chemotherapy-induced gastrointestinal toxicity in pediatric cancer patients, Support of immune recovery and reduction of infection risk in hematopoietic stem cell transplant recipients.

At a glance

Generic nameLactobacillus plantarum strain 299
Also known asDSM 6595, LACTOBACILLUS PLANTARUM 299
SponsorChildren's Oncology Group
Drug classLive biotherapeutic product / Probiotic
ModalityBiologic
Therapeutic areaOncology / Immunology
PhasePhase 3

Mechanism of action

This live biotherapeutic product colonizes the gastrointestinal tract and produces metabolites that strengthen the intestinal epithelial barrier, reduce pathogenic bacterial translocation, and promote regulatory T cell differentiation. By restoring eubiotic conditions and enhancing mucosal immunity, it may reduce treatment-related toxicities and support immune recovery in cancer patients undergoing chemotherapy or hematopoietic stem cell transplantation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: